NVCT - Nuvectis Pharma, Inc.

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
Total revenue
0
0
0
Operating expenses
Research development
13,227
13,227
9,545
Selling general and administrative
6,007
6,007
3,349
Total operating expenses
19,234
19,234
12,894
Operating income or loss
-19,234
-19,234
-12,894
Income before tax
-19,085
-19,085
-12,890
Income from continuing operations
-19,085
-19,085
-12,890
Net income
-19,085
-19,085
-12,890
Net income available to common shareholders
-19,085
-19,085
-12,890
Basic EPS
-
-1.51
-1.09
Diluted EPS
-
-1.51
-1.09
Basic average shares
-
12,658
12,718
Diluted average shares
-
12,658
12,718
EBITDA
-
-19,234
-12,894